DNLI cites strong AVLAYAH launch and pipeline progress
Denali Therapeutics highlighted a strong AVLAYAH launch, robust pipeline progress, and global expansion plans, with key program data readouts expected in 2027–2028. Strategy centers on a multi-product enzyme franchise and advancing Alzheimer’s and FTD programs.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.